-
Mashup Score: 0Neoadjuvant immunotherapy effective regardless of race in triple-negative breast cancer - 2 year(s) ago
Results of a phase 1/phase 2 study showed similar treatment outcomes among Black and non-Black women who received durvalumab plus chemotherapy prior to surgery for triple-negative breast cancer.Data published in Clinical Cancer Research revealed no statistically significant differences in efficacy outcomes according to race and no additional treatment-related adverse events.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
We evaluated the efficacy of adjuvant durvalumab after neoadjuvant concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC).
Source: Esmo OpenCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adjuvant #durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, #phaseII study @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/LqnPFj7EPg https://t.co/ImpzlKAfDb
-
-
Mashup Score: 2
The Phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression after definitive chemoradiotherapy (CRT). The observational PACIFIC-R study assesses the real-world effectiveness of durvalumab in patients from an early access program (EAP). Here, we report…
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
PACIFIC-R: An ongoing, international, retrospective study of patients who started #durvalumab within an #EAP between September 2017 - December 2018. https://t.co/QipRsvXvop #LCSM @nicogirardcurie @vilded @bensolomon1 @AndrearicFili @Piuchagarrido https://t.co/bvF2jF6gKo
-
-
Mashup Score: 1FDA Approves Tremelimumab Plus Durvalumab in Unresectable HCC - 2 year(s) ago
Based on results from the phase 3 HIMALAYA trial, the FDA has approved tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma.
Source: Cancer NetworkCategories: Latest Headlines, UrologyTweet-
RT @Amitmahipal79: FDA Approves #Tremelimumab Plus #Durvalumab in Unresectable #HCC https://t.co/UT48owifUJ via @CancerNetwrk @AstraZenecaU…
-
-
Mashup Score: 0Dowlati Compares the Advantages and Disadvantages of Atezolizumab and Durvalumab in ES-SCLC - 2 year(s) ago
During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of #atezolizumab and #durvalumab as therapy for patients with small cell lung cancer. #lcsm #sclc # https://t.co/dSkak4AEaS https://t.co/2GvWXuHdOv
-
-
Mashup Score: 0Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial - 2 year(s) ago
The combination of durvalumab and tremelimumab is an active treatment regimen for advanced or metastatic sarcoma and merits evaluation in specific subsets in future trials.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in the September issue: #Durvalumab plus #tremelimumab in advanced or metastatic soft tissue and bone #sarcomas: a single-centre phase 2 trial https://t.co/Zt9vTFzBOK https://t.co/ACfsCFGbzs
-
-
Mashup Score: 0
The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Tremelimumab plus #durvalumab and #chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations. #nsclc #WCLC22 https://t.co/NU2i1WFiim
-
-
Mashup Score: 0Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial - 2 year(s) ago
The combination of durvalumab and tremelimumab is an active treatment regimen for advanced or metastatic sarcoma and merits evaluation in specific subsets in future trials.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: #Durvalumab plus #tremelimumab in advanced or metastatic soft tissue and bone #sarcomas: a single-centre phase 2 trial https://t.co/Zt9vTFzBOK https://t.co/BP7fz9FWRw
-
-
Mashup Score: 4Chemotherapy plus durvalumab combinations show promise in advanced biliary tract cancer - 2 year(s) ago
Gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, produced favorable outcomes as first-line treatment for advanced biliary tract cancer, according to research. “Immune checkpoint inhibitors have been assessed in biliary tract cancer and have shown clinical activity,” Do-Youn Oh, MD, of the division of medical oncology at Seoul National University
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: #Chemotherapy plus #durvalumab combinations show promise in advanced #biliarytractcancer @HemOncToday @LancetGastroHep #GITwitter #MedTwitter https://t.co/lUw4kodYbY
-
-
Mashup Score: 1Adding Durvalumab to Chemotherapy Does Not Improve Outcomes in MDS | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination March 30, 2022 Combining the checkpoint inhibitor durvalumab with standard of care azacitidine did not improve the response rate among treatment-naïve patients with higher-risk…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
The combination of #durvalumab with #azacitidine was not found to improve response rates among treatment-naïve patients with higher-risk #MDS, nor did the addition of frontline #daratumumab to azacitidine improve outcomes in patients with #AML https://t.co/c8Mu97yEMp
-
#BreastCancerAwarenessMonth ICYMI: Neoadjuvant immunotherapy effective regardless of race in triple-negative #breastcancer. https://t.co/lFwu0YGam3 #durvalumab #neoadjuvanttherapy @YaleCancer @YaleMed #racialdisparity #HemOnc #Oncology #MedEd